跳至主要内容
临床试验/NCT00116363
NCT00116363Unknown2 期

Phase II Study Examining the Biological Efficacy of Intratumoral INGN 241 (Ad-mda7) Administration in Patients With In Transit Melanoma

Introgen Therapeutics2 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2005年3月1日最近更新:
适应症

试验速览

阶段
2 期
发起方
入组人数
25
试验地点
2
主要终点
anti-tumor effects and systemic immune activation at 28 days

研究概览

简要总结

This is a research study to look at the ways in which a treatment called INGN241 can kill melanoma cells or help the patient's immune system kill melanoma cells.

详细描述

INGN 241 is an adenoviral vector carrying the MDA-7 cDNA. MDA-7 is a novel tumor suppressor molecule with cytokine properties, recently designated as IL-24. Over expression of MDA-7 in melanoma cells in vitro has been shown to inhibit cellular proliferation and induce apoptosis. Loss of MDA-7 expression in human melanomas has been shown to correlate with invasion and metastasis. The INGN 241 gene transfer construct has been previously used in human subjects in an ongoing open label Phase I study using intratumoral administration, and has been well tolerated to date. The primary objectives of the present study are to determine if INGN 241, injected into a melanoma in transit lesion, can induce apoptosis in regional uninjected lesions and initiate systemic immune activation. Secondary objectives include examination of specific immunity and of clinical response and toxicity.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically proven melanoma, must have 3 regional metastatic lesions that are in transit

排除标准

  • Central nervous system involvement by melanoma

结局指标

主要结局

anti-tumor effects and systemic immune activation at 28 days

次要结局

  • tumor response
  • toxicity and safety
  • the induction of antigen-specific T-lymphocytes after multiple cycles of treatment

研究者

发起方
Introgen Therapeutics
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验